Skip to main content

Herbert Kim Lyerly, MD

George Barth Geller Distinguished Professor of Immunology
Professor of Surgery
Professor in Immunology
Professor of Pathology
Office: 203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710
Campus Mail: DUMC Box 2606 Med Ctr, Durham, NC 27710

Education and Training

  • M.D., University of California - Los Angeles, 1983

Selected Grants

Publications

Song, Linan, Shuo Wang, Tong Fang, Xiaoguang Qiu, Xiaoli Wang, Xinna Zhou, Michael A. Morse, et al. “Changes in peripheral blood regulatory T cells, and IL-6 and IL-10 levels predict response of pediatric medulloblastoma and germ cell tumors with residual or disseminated disease to craniospinal irradiation.” Int J Radiat Oncol Biol Phys, May 8, 2021. https://doi.org/10.1016/j.ijrobp.2021.04.041.

Full Text

Telli, Melinda L., Hiroshi Nagata, Irene Wapnir, Chaitanya R. Acharya, Kaitlin Zablotsky, Bernard A. Fox, Carlo B. Bifulco, et al. “Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.” Clin Cancer Res 27, no. 9 (May 1, 2021): 2481–93. https://doi.org/10.1158/1078-0432.CCR-20-3944.

Full Text

Wang, Jie, Takuya Osada, Michael A. Morse, Frank Calzone, Hai Yan, Dung Thai, and H Kim Lyerly. “Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.” Leuk Lymphoma, February 12, 2021, 1–6. https://doi.org/10.1080/10428194.2021.1881504.

Full Text

Crosby, Erika J., Hiroshi Nagata, Melinda L. Telli, Chaitanya R. Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients.” In Cancer Research, Vol. 81, 2021.

Scholars@Duke

Crosby, Erika J., H Kim Lyerly, and Zachary C. Hartman. “Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.” Oncotarget 12, no. 1 (January 5, 2021): 1–3. https://doi.org/10.18632/oncotarget.27861.

Full Text

Wang, Xiaoli, Guoliang Qiao, Ni Jiang, Michael A. Morse, Xinna Zhou, Shuo Wang, Jiangping Wu, et al. “Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.” Am J Cancer Res 11, no. 4 (2021): 1709–18.

Scholars@Duke

Wang, Jie, Michael Morse, Frank Calzone, Hai Yan, Zung Thai, Takuya Osada, and Herbert Lyerly. “Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition.” In Blood, 136:4–5. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-140576.

Full Text

Crosby, Erika, Hiroshi Nagata, Melinda Telli, Chaitanya Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer.” In Journal for Immunotherapy of Cancer, 8:A838–A838. BMJ, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0789.

Full Text

Crosby, Erika J., Amy C. Hobeika, Donna Niedzwiecki, Christel Rushing, David Hsu, Peter Berglund, Jonathan Smith, et al. “Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.” J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001662.

Full Text

Bhatnagar, Vishal, Stacie Hudgens, Elisabeth Piault-Louis, Lee Jones, Julia A. Beaver, H Kim Lyerly, Gregory Reaman, Thomas Fleming, and Paul G. Kluetz. “Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.” Oncologist 25, no. 10 (October 2020): 819–21. https://doi.org/10.1634/theoncologist.2020-0062.

Full Text

Pages